Page last updated: 2024-10-31

metoclopramide and Genital Neoplasms, Female

metoclopramide has been researched along with Genital Neoplasms, Female in 9 studies

Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.

Genital Neoplasms, Female: Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).

Research Excerpts

ExcerptRelevanceReference
"Successful control of vomiting was achieved in the first 24 hours, in 74% of the cycles containing cisplatin and 82% of the cycles without cisplatin, if ondansetron was used."9.08Ondansetron in chemotherapy-induced emesis. Our experience. ( Bandiera, AF; Fiorelli, C; Framarino dei Malatesta, M; Marzetti, L; Toccaceli Blasi, MR; Veneziano, M; Yacoub, M, 1995)
" We compared the efficacy, toxicity, and patients' preference for tropisetron, a new 5-hydroxytryptamine3 (HT3) receptor antagonist, with those of a combination of high-dose metoclopramide, dexamethasone, diphenhydramine, and lorazepam (metoclopramide cocktail) in a randomized crossover study for the control of nausea and vomiting during cisplatin-containing chemotherapy."9.08Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis. ( Chang, TC; Cheng, HH; Hsieh, F; Lai, CH; Li, CL; Michael, BJ; Soong, YK; Tseng, CJ, 1996)
") was compared with a metoclopramide cocktail for the prevention of nausea and emesis."9.07An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. ( Frankendal, B; Hallén, C; Sorbe, B, 1994)
"Successful control of vomiting was achieved in the first 24 hours, in 74% of the cycles containing cisplatin and 82% of the cycles without cisplatin, if ondansetron was used."5.08Ondansetron in chemotherapy-induced emesis. Our experience. ( Bandiera, AF; Fiorelli, C; Framarino dei Malatesta, M; Marzetti, L; Toccaceli Blasi, MR; Veneziano, M; Yacoub, M, 1995)
" We compared the efficacy, toxicity, and patients' preference for tropisetron, a new 5-hydroxytryptamine3 (HT3) receptor antagonist, with those of a combination of high-dose metoclopramide, dexamethasone, diphenhydramine, and lorazepam (metoclopramide cocktail) in a randomized crossover study for the control of nausea and vomiting during cisplatin-containing chemotherapy."5.08Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis. ( Chang, TC; Cheng, HH; Hsieh, F; Lai, CH; Li, CL; Michael, BJ; Soong, YK; Tseng, CJ, 1996)
") was compared with a metoclopramide cocktail for the prevention of nausea and emesis."5.07An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. ( Frankendal, B; Hallén, C; Sorbe, B, 1994)
"This pilot randomized study compared MDL 72,222, a highly selective 5-HT3 receptor antagonist, with a high-dose metoclopramide regimen (HDM) for chemotherapy-induced nausea and vomiting."5.07Randomized comparison of the antiemetic efficacy of a serotonin type 3 receptor antagonist (MDL 72,222) with a high-dose metoclopramide regimen. ( Barrett, RJ; Hahne, WF; Heck, K; Homesley, HD; Lentz, SS; Lovelace, JV; McLees, B; Woodlief, L, 1993)
"Metoclopramide was given intravenously 4 times during a 6-hour period (1/2 h before and 1 1/2, 3 1/2 and 5 1/2 h after cytostatic treatment) in a total dose of 1, 2, 4, 6, or 8 mg/kg."1.27High-dose metoclopramide in the treatment of cis-platinum induced emesis. A dose-finding study. ( Danneskiold-Samsøe, P; Hauksson, A; Tropé, C, 1985)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19904 (44.44)18.7374
1990's5 (55.56)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Framarino dei Malatesta, M1
Veneziano, M1
Fiorelli, C1
Bandiera, AF1
Yacoub, M1
Toccaceli Blasi, MR1
Marzetti, L1
Sorbe, B1
Hallén, C1
Frankendal, B1
Homesley, HD1
Hahne, WF1
McLees, B1
Heck, K1
Barrett, RJ1
Lentz, SS1
Woodlief, L1
Lovelace, JV1
Chang, TC1
Hsieh, F1
Lai, CH1
Tseng, CJ1
Cheng, HH1
Li, CL1
Michael, BJ1
Soong, YK1
Malone, JM1
Christensen, CW1
Yashinsky, D1
Malviya, VK1
Deppe, G1
Hayashi, Y1
Iwasaka, T1
Hachisuga, T1
Fukuda, K1
Tanaka, T1
Matsuo, N1
Sugimori, H1
Krebs, HB1
Myers, MB1
Wheelock, JB1
Goplerud, DR1
Benrubi, GI1
Norvell, M1
Nuss, RC1
Robinson, H1
Tropé, C1
Danneskiold-Samsøe, P1
Hauksson, A1

Trials

7 trials available for metoclopramide and Genital Neoplasms, Female

ArticleYear
Ondansetron in chemotherapy-induced emesis. Our experience.
    European journal of gynaecological oncology, 1995, Volume: 16, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Genital Neoplas

1995
An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
    Cancer chemotherapy and pharmacology, 1994, Volume: 33, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Drug Administration Schedule; Female; Genita

1994
Randomized comparison of the antiemetic efficacy of a serotonin type 3 receptor antagonist (MDL 72,222) with a high-dose metoclopramide regimen.
    American journal of clinical oncology, 1993, Volume: 16, Issue:2

    Topics: Adult; Aged; Antiemetics; Cisplatin; Diphenhydramine; Drug Therapy, Combination; Female; Genital Neo

1993
Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis.
    Cancer chemotherapy and pharmacology, 1996, Volume: 37, Issue:3

    Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cross-Over Studies; Drug Therapy, Combin

1996
Prochlorperazine and transdermal scopolamine added to a metoclopramide antiemetic regimen. A controlled comparison.
    The Journal of reproductive medicine, 1990, Volume: 35, Issue:10

    Topics: Administration, Cutaneous; Cisplatin; Female; Genital Neoplasms, Female; Humans; Infusions, Intraven

1990
Combination antiemetic therapy in cisplatin-induced nausea and vomiting.
    Cancer, 1985, Jun-01, Volume: 55, Issue:11

    Topics: Adult; Aged; Antiemetics; Cisplatin; Clinical Trials as Topic; Drug Therapy, Combination; Female; Ge

1985
The use of methylprednisolone and metoclopramide in control of emesis in patients receiving cis-platinum.
    Gynecologic oncology, 1985, Volume: 21, Issue:3

    Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Double-Blind Me

1985

Other Studies

2 other studies available for metoclopramide and Genital Neoplasms, Female

ArticleYear
[Antiemetic efficacy of high-dose metoclopramide, diphenhydramine, methylprednisolone and diazepam on chemotherapy-induced emesis in gynecological malignancy].
    Nihon Sanka Fujinka Gakkai zasshi, 1988, Volume: 40, Issue:7

    Topics: Adult; Aged; Cisplatin; Diazepam; Diphenhydramine; Drug Therapy, Combination; Female; Genital Neopla

1988
High-dose metoclopramide in the treatment of cis-platinum induced emesis. A dose-finding study.
    Neoplasma, 1985, Volume: 32, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Genital Neoplasms, Fem

1985